REMARKS

The Office Action of April 22, 2002 has been received and reviewed. Claims 1-9, 12 and 14-17 are pending in the application and claims 14-17 stand rejected. Claims 10, 11 and 13 were previously cancelled. Claims 1-9 and 12 were withdrawn. Applicant proposes to amend claims 14-16 as set forth herein. All amendments and cancellations are made without prejudice or disclaimer. Reconsideration is respectfully requested.

Petition to Revive Application

Concurrent herewith, applicant is moving to revive the instant application, which earlier unintentionally went abandoned. The abandonment came about due to miscommunications between applicant, applicant's former U.S. patent counsel, and applicant's former European patent counsel. These amendments and remarks are being submitted together with a Request for Continued Examination and the requisite fee.

Objections to the Specification

Substitute paragraphs have been provided in the Specification. All trademarked names have been capitalized; however, it is noted that cetrorelix, gossypol, buserelin, triptorelin, ramorelix, leuprorelin, goserelin, antide, and tamoxifen are not trademarks and were inadvertently indicated as such in the as-filed specification. To avoid confusion, the trademark symbol was removed from these names. Table I has also been amended to further clarify its contents as reflected in the as-filed specification, as requested.

Reconsideration and withdrawal of the objections to the Specification is requested.

Rejections under 35 U.S.C. § 112, first paragraph

Claims 14-17 stand rejected under 35 U.S.C. § 112, first paragraph, as assertedly lacking enablement. (*See*, Final Office Action, at page 2). Partially in view of the amendments made to claims 14-16, applicant respectfully traverses the rejections as set forth herein.

As amended, independent claim 14 is directed to a method for decreasing cellular replication of a tumor originating in one or more of the brain, nervous system or meninges of the brain comprising administering to a subject a therapeutically effective amount of one or more of a GnRH agonist or GnRH antagonist.

Similarly, as amended, independent claim 15 is directed to a method for decreasing cellular replication of a Kaposi sarcoma comprising administering to a subject a therapeutically effective amount of one or more of a GnRH agonist or GnRH antagonist.

Independent claim 15, as proposed to be amended, is directed to a method for preventing cellular replication of GnRH-positive oat-cell carcinoma, malignant melanoma, Kaposi sarcoma, or proliferating glioma comprising administering to a subject a TGF-β decreasing amount of a GnRH analog, said GnRH analog being a GnRH agonist.

Similarly, independent claim 16, as amended, is directed to a method for decreasing cellular replication of a Glioblastoma multiforme, medulloblastoma, pinealoma, neuroblastoma, craniopharyngeoma, meningeoma, chordoma, Ewing sarcoma, malignant melanoma, or Kaposi sarcoma comprising administering to a subject a therapeutically effective amount of one or more of a GnRH agonist or GnRH antagonist.

The as-filed specification discloses the use of these GnRH peptide analog agonists. (*See*, Specification, as filed, at page 13). Additional support for the amendments to claims 14-16 can be found in the as-filed Specification, especially at page 10, line 29 through page 11, line 4, page 15, lines 5-18, and in the Examples section, at page 22, Examples 11-13, page 22, line 1 through page 23, line 26.

Reconsideration and withdrawal of the enablement rejections of independent claims 14-16, and dependent claim 17, are requested.

CONCLUSION

In view of the foregoing amendments and remarks, applicant respectfully submits that the claims define patentable subject matter. Should the Office determine that additional issues remain which might be resolved by a telephone conference, the Office is invited to contact applicant's attorney at the address or telephone number given herein.

Respectfully submitted,

Allen C. Turner
Registration No. 33,041
Attorney for Applicant
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: August 16, 2005

Document in ProLaw